Methods of using zalpha11 ligand
AssigneeZymoGenetics, Inc.
InventorsJulia E. Novak, Scott R. Presnell, Cindy A. Sprecher, Donald C. Foster, Richard D. Holly, Jane A. Gross, Janet V. Johnston, Andrew J. Nelson, Stacey R. Dillon, Angela K. Hammond
Life of this patent
Estimating the term…
Abstract
The present invention relates to zalpha11 Ligand polynucleotide and polypeptide molecules. The zalpha11 Ligand is a novel cytokine. The polypeptides may be used within methods for stimulating the proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
Claims21
A method of stimulating an immune response in a mammal exposed to an antigen or pathogen comprising the steps of:
- (1) determining directly or indirectly the level of antigen or pathogen present in said mammal;
- (2) administering a composition comprising zalpha11 Ligand polypeptide comprising an amino acid sequence as shown in SEQ ID NO:2 from amino acid residue 32 to amino acid residue 162 in an acceptable pharmaceutical vehicle;
- (3) determining directly or indirectly the level of antigen or pathogen in said mammal;
- and
- (4) comparing the level of the antigen or pathogen in step 1 to the antigen or pathogen level in step 3, wherein a change in the level is indicative of stimulating an immune response.
A method of stimulating an immune response in a mammal exposed to an antigen or pathogen comprising:
- (1) determining a level of an antigen- or pathogen-specific antibody;
- (2) administering a composition comprising zalpha11 Ligand polypeptide comprising an amino acid sequence as shown in SEQ ID NO:2 from amino acid residue 32 to amino acid residue 162 in an acceptable pharmaceutical vehicle;
- (3) determining a post administration level of said antigen- or pathogen-specific antibody;
- (4) comparing the level of said antibody in step (1) to the level of said antibody in step (3), wherein an increase in said antibody level is indicative of stimulating an immune response.
A method of stimulating an immune response in a mammal exposed to an antigen comprising administering to the mammal a therapeutically effective amount of zalpha11 Ligand comprising an amino acid sequence as shown in SEQ ID NO:2 from amino acid residue 32 to amino acid residue 162.
A method of stimulating an immune response in a mammal bearing a tumor comprising administering a therapeutically effective amount of zalpha11 Ligand comprising an amino acid sequence as shown in SEQ ID NO:2 from amino acid residue 32 to amino acid residue 162 to the mammal, wherein the stimulation of the immune response results in an increased capacity of the immune cells to react with the tumor.
A method of stimulating an immune response in a mammal bearing a tumor comprising administering a therapeutically effective amount of zalpha11 Ligand comprising an amino acid sequence as shown in SEQ ID NO:2 from amino acid residue 32 to amino acid residue 162 to the mammal, wherein the stimulation of the immune response results in enhancing an anti-tumor activity.
Dependencies are inferred from the claim text.